Powerful Medical
New York
About Powerful Medical
Heart attacks cause 12 million deaths annually, yet 50% are initially misdiagnosed, doubling mortality rates. Our AI outperforms the top 1% of cardiologists in heart attack detection, identifying critical cases earlier and more accurately. This has the potential to reduce heart attack deaths by 75% within five years while delivering significant financial benefits to hospitals - boosting revenue through accurate STEMI triage, reducing false positives, and freeing up critical beds faster. Beyond heart attacks, we’re already certified for 38 additional ECG-based diagnoses like arrhythmias and heart failure, positioning PMcardio as the AI-driven standard for cardiovascular care. As of October 2024, we’ve onboarded 60,000 healthcare professionals to PMcardio, screening 1.1 million patients. We’re working with leading health systems like Mount Sinai, Duke Health, Presbyterian, SSM Health & many others. We’re scaling fast to bring AI-driven decision-making to every step of the cardiovascular care pathway. To date, there are over 30 internal and external publications on PMcardio’s AIs, including 6,000 patients enrolled in a RCT, further validating our clinical impact. We’ve built a world-class team of entrepreneurs, physicians, software engineers and executives from healthcare unicorns, alongside senior advisors from leading providers and payers, as well as two former presidents of cardiology associations shaping clinical guidelines for heart attack care, and a former FDA director.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 51 – 100
- Estimated revenue: $10K – $50K
- Total funding: $62.6M
- Funding stage: Seed
- Last round: Grant (Jul 2025)
- Website: powerfulmedical.com
- Phone: [email protected]
Industries & Categories
Artificial Intelligence (AI), Big Data, Health Care, Health Diagnostics, Image Recognition
Social Profiles
Canonical: https://fsome.com/organization/powerful-medical-94025 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.